Fluoxetine prevents the development of depressive-like behavior in a mouse model of cancer related fatigue

Physiology and Behavior

Volumn 140, Issue , 2015, Pages 230-235

  Norden, Diana M ^a   Devine, Raymond ^a   Bicer, Sabahattin ^a   Jing, Runfeng ^a   Reiser, Peter J ^a   Wold, Loren E ^a   Godbout, Jonathan P ^a   McCarthy, Donna O ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b MARQUETTE UNIVERSITY   (United States)

Author keywords

Cancer; Depression; Fatigue; Fluoxetine; Neuroinflammation; Serotonin

Indexed keywords

FLUOXETINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; KYNURENINE 3 MONOOXYGENASE; ANTIDEPRESSANT AGENT; CYTOKINE; MESSENGER RNA;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CARCASS; CONTROLLED STUDY; DEPRESSION; FATIGUE; FEMALE; GASTROCNEMIUS MUSCLE; HIPPOCAMPUS; LOCOMOTION; MALE; MALIGNANT NEOPLASTIC DISEASE; MOUSE; MUSCLE ATROPHY; MUSCLE MASS; NONHUMAN; PROTEIN EXPRESSION; SPLEEN WEIGHT; TUMOR CELL INOCULATION; TUMOR GROWTH; TUMOR VOLUME; WEIGHT REDUCTION; ADENOCARCINOMA; ANIMAL; BAGG ALBINO MOUSE; BRAIN; COLON TUMOR; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; MOTOR ACTIVITY; NONPARAMETRIC TEST; ORAL DRUG ADMINISTRATION; TIME FACTOR;

ADENOCARCINOMA; ADMINISTRATION, ORAL; ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BRAIN; COLONIC NEOPLASMS; CYTOKINES; DEPRESSION; DISEASE MODELS, ANIMAL; FATIGUE; FEMALE; FLUOXETINE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LOCOMOTION; MICE; MICE, INBRED BALB C; MOTOR ACTIVITY; RNA, MESSENGER; STATISTICS, NONPARAMETRIC; TIME FACTORS;

EID: 84920278616     PISSN: 00319384     EISSN: 1873507X     Source Type: Journal    
DOI: 10.1016/j.physbeh.2014.12.045     Document Type: Article

References (44)

1. Berger A.M., Abernethy A.P., Atkinson A., Barsevick A.M., Breitbart W.S., Cella D., Cimprich B., Cleeland C., Eisenberger M.A., Escalante C.P., et al. Cancer-related fatigue. J. Natl. Compr. Cancer Netw. 2010, 8:904-931.
2. Bower J.E., Lamkin D.M. Inflammation and cancer-related fatigue: mechanisms, contributing factors, and treatment implications. Brain Behav. Immun. 2013, 30:S48-S57. (Suppl.).
3. Husson O., Nieuwlaat W.A., Oranje W.A., Haak H.R., van de Poll-Franse L.V., Mols F. Fatigue Among short- and long-term thyroid cancer survivors: results from the population-based PROFILES Registry. Thyroid 2013, 23:1247-1255.
4. Minton O., Alexander S., Stone P.C. Identification of factors associated with cancer related fatigue syndrome in disease-free breast cancer patients after completing primary treatment. Breast Cancer Res. Treat. 2012, 136:513-520.
5. Bower J.E., Ganz P.A., Irwin M.R., Kwan L., Breen E.C., Cole S.W. Inflammation and behavioral symptoms after breast cancer treatment: do fatigue, depression, and sleep disturbance share a common underlying mechanism?. J. Clin. Oncol. 2011, 29:3517-3522.
6. Kim H.J., Barsevick A.M., Fang C.Y., Miaskowski C. Common biological pathways underlying the psychoneurological symptom cluster in cancer patients. Cancer Nurs. 2012, 35:E1-E20.
7. Pertl M.M., Hevey D., Boyle N.T., Hughes M.M., Collier S., O'Dwyer A.M., Harkin A., Kennedy M.J., Connor T.J. C-reactive protein predicts fatigue independently of depression in breast cancer patients prior to chemotherapy. Brain Behav. Immun. 2013, 34:108-119.
8. Schmidt M.E., Chang-Claude J., Seibold P., Vrieling A., Heinz J., Flesch-Janys D., Steindorf K. Determinants of long-term fatigue in breast cancer survivors: results of a prospective patient cohort study. Psycho-Oncology 2014, (Epub ahead of print, 04, May 17). 10.1002/pon3581.
9. Morrow G.R., Hickok J.T., Roscoe J.A., Raubertas R.F., Andrews P.L., Flynn P.J., Hynes H.E., Banerjee T.K., Kirshner J.J., King D.K. Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program. J. Clin. Oncol. 2003, 21:4635-4641.
10. Roscoe J.A., Morrow G.R., Hickok J.T., Mustian K.M., Griggs J.J., Matteson S.E., Bushunow P., Qazi R., Smith B. Effect of paroxetine hydrochloride (Paxil) on fatigue and depression in breast cancer patients receiving chemotherapy. Breast Cancer Res. Treat. 2005, 89:243-249.
11. Jean-Pierre P., Morrow G.R., Roscoe J.A., Heckler C., Mohile S., Janelsins M., Peppone L., Hemstad A., Esparaz B.T., Hopkins J.O. A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research base study. Cancer 2010, 116:3513-3520.
12. Saligan L.N., Kim H.S. A systematic review of the association between immunogenomic markers and cancer-related fatigue. Brain Behav. Immun. 2012, 26:830-848.
13. Wood L.J., Weymann K. Inflammation and neural signaling: etiologic mechanisms of the cancer treatment-related symptom cluster. Curr. Opin. Support. Palliat. Care 2013, 7:54-59.
14. Henry C.J., Huang Y., Wynne A., Hanke M., Himler J., Bailey M.T., Sheridan J.F., Godbout J.P. Minocycline attenuates lipopolysaccharide (LPS)-induced neuroinflammation, sickness behavior, and anhedonia. J. Neuroinflammation 2008, 5:15.
15. Haroon E., Raison C.L., Miller A.H. Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacology 2012, 37:137-162.
16. Carmichael M.D., Davis J.M., Murphy E.A., Brown A.S., Carson J.A., Mayer E.P., Ghaffar A. Role of brain IL-1beta on fatigue after exercise-induced muscle damage. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2006, 291:R1344-R1348.
17. Norden D.M., Bicer S., Clark Y., Jing R., Henry C.J., Wold L.E., Reiser P.J., Godbout J.P., McCarthy D.O. Tumor growth increases neuroinflammation, fatigue and depressive-like behavior prior to alterations in muscle function. Brain Behav. Immun. 2015, 43:76-85.
18. Raison C.L., Dantzer R., Kelley K.W., Lawson M.A., Woolwine B.J., Vogt G., Spivey J.R., Saito K., Miller A.H. CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression. Mol. Psychiatry 2010, 15:393-403.
19. Dantzer R., O'Connor J.C., Lawson M.A., Kelley K.W. Inflammation-associated depression: from serotonin to kynurenine. Psychoneuroendocrinology 2011, 36:426-436.
20. Haase J., Brown E. Integrating the monoamine, neurotrophin and cytokine hypotheses of depression - a central role for the serotonin transporter?. Pharmacol. Ther. 2014, (Epub ahead of print). 10.1016/j.pharmthera.2014.10.002.
21. Dwarkasing J.T., van Dijk M., Dijk F.J., Boekschoten M.V., Faber J., Argiles J.M., Laviano A., Muller M., Witkamp R.F., van Norren K. Hypothalamic food intake regulation in a cancer-cachectic mouse model. J. Cachex. Sarcopenia Muscle 2014, 5:159-169.
22. Cosper P.F., Leinwand L.A. Cancer causes cardiac atrophy and autophagy in a sexually dimorphic manner. Cancer Res. 2011, 71:1710-1720.
23. Yang M., Kim J., Kim J.-S., Kim S.-H., Kim J.-C., Kang M.-J., Jung U., Shin T., Wang H., Moon C. Hippocampal dysfunctions in tumor-bearing mice. Brain Behav. Immun. 2014, 36:147-155.
24. Xu H., Crawford D., Hutchinson K.R., Youtz D.J., Lucchesi P.A., Velten M., McCarthy D.O., Wold L.E. Myocardial dysfunction in an animal model of cancer cachexia. Life Sci. 2011, 88:406-410.
25. Graves E., Ramsay E., McCarthy D.O. Inhibitors of COX activity preserve muscle mass in mice bearing the Lewis lung carcinoma, but not the B16 melanoma. Res. Nurs. Health 2006, 29:87-97.
26. Okayama T., Kokura S., Ishikawa T., Adachi S., Hattori T., Takagi T., Handa O., Naito Y., Yoshikawa T. Antitumor effect of pretreatment for colon cancer cells with hyperthermia plus geranylgeranylacetone in experimental metastasis models and a subcutaneous tumor model of colon cancer in mice. Int. J. Hyperth. 2009, 25:141-149.
27. Weber M., Talmon S., Schulze I., Boeddinghaus C., Gross G., Schoemaker H., Wicke K.M. Running wheel activity is sensitive to acute treatment with selective inhibitors for either serotonin or norepinephrine reuptake. Psychopharmacology 2009, 203:753-762.
28. Peterson J.A., Risley D.S., Anderson P.N., Hostettler K.F. Stability of fluoxetine hydrochloride in fluoxetine solution diluted with common pharmaceutical diluents. Am. J. Hosp. Pharm. 1994, 51:1342-1345.
29. Zombeck J.A., Fey E.G., Lyng G.D., Sonis S.T. A clinically translatable mouse model for chemotherapy-related fatigue. Comp. Med. 2013, 63:491-497.
30. Godbout J.P., Moreau M., Lestage J., Chen J., Sparkman N.L., O'Connor J., Castanon N., Kelley K.W., Dantzer R., Johnson R.W. Aging exacerbates depressive-like behavior in mice in response to activation of the peripheral innate immune system. Neuropsychopharmacology 2008, 33:2341-2351.
31. Dulawa S.C., Holick K.A., Gundersen B., Hen R. Effects of chronic fluoxetine in animal models of anxiety and depression. Neuropsychopharmacology 2004, 29:1321-1330.
32. Mols F., Husson O., Roukema J.A., van de Poll-Franse L.V. Depressive symptoms are a risk factor for all-cause mortality: results from a prospective population-based study among 3,080 cancer survivors from the PROFILES registry. J. Cancer Surviv. 2013, 7:484-492.
33. Brown L.F., Kroenke K. Cancer-related fatigue and its associations with depression and anxiety: a systematic review. Psychosomatics 2009, 50:440-447.
34. Hopwood N., Maswanganyi T., Harden L.M. Comparison of anorexia, lethargy, and fever induced by bacterial and viral mimetics in rats. Can. J. Physiol. Pharmacol. 2009, 87:211-220.
35. Kirkova J., Aktas A., Walsh D., Davis M.P. Cancer symptom clusters: clinical and research methodology. J. Palliat. Med. 2011, 14:1149-1166.
36. Phillips S.M., McAuley E. Physical activity and fatigue in breast cancer survivors: a panel model examining the role of self-efficacy and depression. Cancer Epidemiol. Biomark. Prev. 2013, 22:773-781.
37. Lim C.M., Kim S.W., Park J.Y., Kim C., Yoon S.H., Lee J.K. Fluoxetine affords robust neuroprotection in the postischemic brain via its anti-inflammatory effect. J. Neurosci. Res. 2009, 87:1037-1045.
38. Roumestan C., Michel A., Bichon F., Portet K., Detoc M., Henriquet C., Jaffuel D., Mathieu M. Anti-inflammatory properties of desipramine and fluoxetine. Respir. Res. 2007, 8:35.
39. Liu D., Wang Z., Liu S., Wang F., Zhao S., Hao A. Anti-inflammatory effects of fluoxetine in lipopolysaccharide(LPS)-stimulated microglial cells. Neuropharmacology 2011, 61:592-599.
40. Kim H., Chen L., Lim G., Sung B., Wang S., McCabe M.F., Rusanescu G., Yang L., Tian Y., Mao J. Brain indoleamine 2,3-dioxygenase contributes to the comorbidity of pain and depression. J. Clin. Invest. 2012, 122:2940-2954.
41. Corona A.W., Norden D.M., Skendelas J.P., Huang Y., O'Connor J.C., Lawson M., Dantzer R., Kelley K.W., Godbout J.P. Indoleamine 2,3-dioxygenase inhibition attenuates lipopolysaccharide induced persistent microglial activation and depressive-like complications in fractalkine receptor (CX(3)CR1)-deficient mice. Brain Behav. Immun. 2013, 31:134-142.
42. Muller N., Schwarz M.J. The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol. Psychiatry 2007, 12:988-1000.
43. Uomoto M., Nishibori M., Nakaya N., Takeuchi Y., Iwagaki H., Tanaka N., Saeki K. Changes in monoamine turnover in the brain of cachectic mice bearing colon-26 tumor cells. J. Neurochem. 1998, 70:260-267.
44. Lyons L., ElBeltagy M., Umka J., Markwick R., Startin C., Bennett G., Wigmore P. Fluoxetine reverses the memory impairment and reduction in proliferation and survival of hippocampal cells caused by methotrexate chemotherapy. Psychopharmacology 2011, 215:105-115.